FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: *Pivot Pharmaceuticals Inc. (the “Issuer”)*

Trading Symbol: *PVOT*

Number of Outstanding Listed Securities: *106,244,230 common shares*

Date: *May 3, 2019*

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

*During April 2019, Pivot continued to prepare itself for commercialization. Pivot signed an agreement with Shopify Inc. to build its online sales channel for the delivery of Pivot's product portfolio. Pivot also signed a letter of intent with Pharmascience Inc. ("Pharmascience") whereby Pharmascience will conduct analytical testing, collaborate on development and research of new medicinal products containing cannabis or cannabis derivatives and drugs containing cannabis and/or cannabis derivatives, provide regulatory support necessary to attain Marketing Authorization, and marketing and distribution of finished pharmaceutical dosage forms.*

*In April 2019, Pivot signed a binding letter of intent with High Park Ventures Inc. (“HPK”), a private investment company, for a non-brokered private placement of $15 million. The private placement will be of units at a price of $0.25 per unit, with each unit consisting of one common share and one common share purchase warrant having a term of two years and an exercise price of $0.35. Completion of the private placement is conditional on HPK satisfactorily completing its due diligence investigation and HPK and Pivot entering into an advisory agreement pursuant to which HPK will provide Pivot with strategic advice.*

1. Provide a general overview and discussion of the activities of management.

*Please see Item 1.*

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

*None.*

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

*None.*

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

*Please see Item 1.*

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

*None.*

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

*None.*

1. Describe the acquisition of new customers or loss of customers.

*Not applicable.*

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

*None.*

1. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

*In April 2019, the employment of two of Pivot’s employees in Pivot Naturals, LLC (“Pivot Naturals”), subsidiary of Pivot, including the President of Pivot Naturals, which was pursuant to written employment contracts, terminated.*

1. Report on any labour disputes and resolutions of those disputes if applicable.

*Not applicable.*

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

*Pursuant to the employment of two of Pivot’s employees in Pivot Naturals having terminated, a demand for arbitration has been filed by these former employees along with an arbitration complaint that alleges claims for breach of the written employment contracts, fraud, illegal retaliation and tortious discharge in violation of public policy seeking, among other things, recovery of accrued and unpaid salary and wages in the total amount of US$213,179 and contractual severance amounts totaling US$475,000 alleged to be due and owing on their alleged involuntary termination, as well as other general and punitive damages. Pivot intends to vigorously defend these claims and file cross-claims against the former employees for breach of contract and related tort claims.*

*Additionally, Pivot has filed suit in British Columbia against these employees of Pivot Naturals for declaratory relief and related matters concerning control and use of Pivot’s assets.*

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

*N/A.*

1. Provide details of any securities issued and options or warrants granted.

*During April 2019, 6,950,000 common shares and share purchase warrants, with exercise price of $0.30 and three year expiry, were issued pursuant to non-brokered financings totalling $1,390,000. Of these common shares and share purchase warrants issued, 4,000,000 common shares and share purchase warrants related to the non-brokered financing of $800,000 completed in March 2019. Pursuant to the non-brokered financings, 508,000 common shares and 108,000 share purchase warrants, with exercise price of $0.30 and three year expiry, were issued for finders’ fees. 60,515 common shares were also issued in April 2019 as an extension fee.*

1. Provide details of any loans to or by Related Persons.

*None.*

1. Provide details of any changes in directors, officers or committee members.

*None.*

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

*None.*

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated May 3, 2019

 Moira Ong
Name of Director or Senior Officer

 *“Moira Ong”*
Signature

Chief Financial Officer
Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***Name of IssuerPivot Pharmaceuticals Inc. | For Month EndApril 2019 | Date of ReportYY/MM/DD2019/05/03 |
| Issuer Address1275 West 6th Avenue, Suite 300 |
| City/Province/Postal CodeVancouver, BC V6H 1A5 | Issuer Fax No.( ) | Issuer Telephone No.( ) |
| Contact NamePatrick Frankham | Contact PositionCEO | Contact Telephone No.514-943-1899 |
| Contact Email Addressinfo@pivotpharma.com | Web Site Addresswww.pivotpharma.com |